Capecitabine Tablets

Active Ingredients: Capecitabine

Capecitabine Tablets are an antineoplastic drug used to treat certain types of cancer, including colon cancer, breast cancer, and colorectal cancer. It is sometimes prescribed for cancer that has become metastatic. Capecitabine may be used alone or in combination with other chemotherapy treatments.

Capecitabine is classified as a nucleoside metabolic inhibitor and an antineoplastic agent. It is a prodrug, which is converted into fluorouracil within the tumor. It works by interfering with DNA synthesis within the cancer cells.

This medication is produced and exported by AdvaCare Pharma. Capecitabine Tablets is manufactured in our facilities in China, India, and the USA. Our factories comply with WHO guidelines and standards, and we regularly inspect these facilities to ensure they meet these high standards.

AdvaCare Pharma manufactures Capecitabine Tablets, one of 40+ oncology treatments, according to rigorous GMP protocols at our state-of-the-art production facility. We are committed to producing quality-assured, cost-effective cancer treatments that meet the highest industry standards and are readily available to cancer patients worldwide. As an established Capecitabine manufacturer, we supply pharmaceutical distributors, hospitals and government institutions with reliable cancer drugs.

What is Capecitabine used for?

Capecitabine may be used to treat cancer that has become metastatic.

How are Capecitabine Tablets used?

This medication is manufactured to be taken orally. This medicine should be taken with a meal or 30 minutes after eating.

What dose should be taken?

For stage III colon cancer (adjuvant), the usual dose is 1250mg/m², per dose, given twice a day during days 1-14 of a 21-day cycle. Repeat for 8 cycles.

For metastatic colorectal cancer, the usual dose is 1250mg/m², per dose, given twice a day during days 1-14 of a 21-day cycle.

For metastatic breast cancer (refractory or relapsed), the usual dose is 1250mg/m², per dose, given twice a day during days 1-14 of a 21-day cycle. When combined with lapatinib, the dose should be decreased to 1000mg/m²/dose. When combined with neratinib, the dose should be decreased to 750mg/m² per dose.

Refer to a doctor or pharmacist for guidelines on dosage.

As with all pharmaceuticals, some unwanted effects can occur from the use of Capecitabine Tablets.

For a comprehensive understanding of all potential side effects, consult a medical professional.

If any symptoms persist or worsen, or you notice any other symptoms, please call your doctor immediately.

This medicine may harm a fetus if the mother or father are being treated. For women, use efficient birth control at least 6 months after the last dose of Capecitabine. For men, use effective birth control at least 3 months after your last treatment. If you or your partner become pregnant, inform a doctor as soon as possible. Do not breastfeed while undergoing treatment with this medicine.

Many drugs are known to interact with Capecitabine, so be sure to check with a doctor before beginning treatment.